文献速递哮喘呼吸道感染

CRTH2拮抗剂对哮喘实验性鼻病毒感染反应的影响:一项初步随机对照试验

Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial.
PubMed 文献 · Thorax · 2021-10-29

这项初步随机对照试验纳入部分控制且使用吸入性糖皮质激素的过敏性哮喘患者,比较替米匹普坦(timapiprant,CRTH2拮抗剂)与安慰剂对实验性鼻病毒A16感染后症状的影响。结果显示,两组在临床急性加重严重程度、病毒载量、抗病毒免疫反应及鼻病毒诱导的气道炎症方面无显著差异,仅安慰剂组支气管活检中CRTH2染色在感染期间增加。替米匹普坦安全性良好,但对鼻病毒感染引起的临床病理变化影响甚微。

要点

  • CRTH2拮抗剂替米匹普坦未能减轻鼻病毒A16诱导的哮喘急性加重严重程度。
  • 替米匹普坦对病毒载量、抗病毒免疫反应及气道炎症无显著影响。
  • 替米匹普坦安全性良好,无死亡、严重不良事件或药物相关退出。

核心结论

  • 替米匹普坦治疗对部分控制哮喘患者鼻病毒A16感染诱导的临床病理变化影响甚微。

研究设计与样本

  • 初步随机对照试验,纳入部分控制且使用维持吸入性糖皮质激素的过敏性哮喘患者,随机分配至替米匹普坦组(n=22)或安慰剂组(n=22),3周后接受鼻病毒A16攻击。

主要发现

  • 主要终点为感染后14天累积下呼吸道症状评分,替米匹普坦组与安慰剂组差异为3.0(95%CI -29.0至17.0),p=0.78。
  • 两组在病毒载量、抗病毒免疫反应或鼻病毒A16诱导的气道炎症方面无差异,惟支气管活检中CRTH2染色在安慰剂组感染期间增加,而替米匹普坦组未增加。
  • 替米匹普坦安全性良好,无死亡、严重不良事件或药物相关退出。

局限性

  • 6例受试者退出研究,8例未感染,最终仅16例替米匹普坦组和14例安慰剂组成功感染受试者纳入结局评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) antagonist timapiprant improved lung function and asthma control in a phase 2 study, with evidence suggesting reduced exacerbations. We aimed to assess whether timapiprant attenuated or prevented asthma exacerbations induced by experimental rhinovirus (RV) infection. We furthermore hypothesised that timapiprant would dampen RV-induced type 2 inflammation and consequently improve antiviral immune responses. METHODS: Atopic patients with partially controlled asthma on maintenance inhaled corticosteroids were randomised to timapiprant (n=22) or placebo (n=22) and challenged with RV-A16 3 weeks later. The primary endpoint was the cumulative lower respiratory symptom score over the 14 days post infection. Upper respiratory symptoms, spirometry, airway hyperresponsiveness, exhaled nitric oxide, RV-A16 virus load and soluble mediators in upper and lower airways samples, and CRTH2 staining in bronchial biopsies were additionally assessed before and during RV-A16 infection. RESULTS: Six subjects discontinued the study and eight were not infected; outcomes were assessed in 16 timapiprant-treated and 14 placebo-treated, successfully infected subjects. There were no differences between treatment groups in clinical exacerbation severity including cumulative lower respiratory symptom score day 0-14 (difference 3.0 (95% CI -29.0 to 17.0), p=0.78), virus load, antiviral immune responses, or RV-A16-induced airway inflammation other than in the bronchial biopsies, where CRTH2 staining was increased during RV-A16 infection in the placebo-treated but not the timapiprant-treated group. Timapiprant had a favourable safety profile, with no deaths, serious adverse events or drug-related withdrawals. CONCLUSION: Timapiprant treatment had little impact on the clinicopathological changes induced by RV-A16 infection in partially controlled asthma.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Farne, Glanville, Johnson, et al. Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial. Thorax. 2021. PMID: 34716281. doi:10.1136/thoraxjnl-2021-217429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。